Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Shareholder Meeting (December 2023)
43 slides from Coloplast A/s Class B's shareholder meeting presentation, Dec 6, 2023
Slide 1: Coloplast Annual General Meeting 2022/23
Jürgen | User of ostomy products Coloplast Annual General Meeting 2022/23
Slide 2: Chairman of the Board Lars Rasmussen
Chairman of the Board Lars Rasmussen 2
Slide 3: Board of Directors: Other shareholder-elected members
Board of Directors Other shareholder-elected Board members Annette Brüls Carsten Hellmann Marianne Wiinholt Jette Nygaard-Andersen 3
Slide 4: Board of Directors: Employee-elected members
Board of Directors Employee-elected Board members Thomas Barfod Roland Vendelbo Pedersen Nikolaj Kyhe Gundersen 4
Slide 5: Executive Leadership Team
Executive Leadership Team Kristian Villumsen Nicolai Buhl Andersen President & CEO Executive Vice President, Innovation Anders Lonning-Skovgaard Paul Marcun Executive Vice President & Executive Vice CFO President, Growth Allan Rasmussen Dorthe Rønnau Executive Vice President, Senior Vice President,
Slide 6: Coloplast Annual General Meeting
Jürgen Coloplast Annual Eva | catheter user Bruger af stomiprodukter General Meeting 2022/23
Slide 7: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 8: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 9: Chairman of the Board Lars Rasmussen
Chairman of the Board Lars Rasmussen 9
Slide 10: This year, Coloplast helped more than 2,000,000 people
This year, Coloplast helped more than 2,000,000 people with intimate healthcare needs Jason | catheter user 10
Slide 11: Solid performance despite external challenges
NEW IMAGE Solid performance despite external challenges Organic Return on EBIT margin growth invested capital 8% 28% * 17% * ** *before special items **before special items after tax 11 Walton | user of ostomy products
Slide 12: Strive25 – focus on innovation and growth
Strive25 – focus on innovation and growth Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 12 Yunguang | wound care patient
Slide 13: Kereclis
Kereclis
Slide 14: Atos
Atos Breathing-Speaking-Living atosmedical.com
Slide 15: Strive25 – focus on innovation and growth
Strive25 – focus on innovation and growth Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 15 Yunguang | wound care patient
Slide 16: Strive25 - Innovation
Strive25 - Innovation Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 16
Slide 17: Personalised Care
Solid progress within innovation Personalised Care 17
Slide 18: Strive25 - Innovation
Strive25 - Innovation Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 19
Slide 19: Strive25 - Growth
Strive25 - Growth Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 20
Slide 20: Strive25 - Sustainability
Strive25 - Sustainability Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 21
Slide 21: Coloplast has set ambitious 2030 targets for sustainability
Coloplast has set ambitious 2030 targets for sustainability
Slide 22: Strive25 – Efficiency
Strive25 – Efficiency Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 23
Slide 23: Strive25 – Leadership, culture and organisation
Strive25 – Leadership, culture and organisation Continence Care Ostomy Care Voice and Respiratory Care Interventional Advanced Wound Care Urology Innovation Leadership, culture and organisation Efficiency Sustainability 24
Slide 24: Key ratios 2022/23
Key ratios 2022/23 Mio. kroner 2022/23 2021/22 Change Net revenue 24,500 22,579 9% Gross margin 67% 69% -2 pp Operating profit (EBIT) 6,845* 6,910* -1% Operating margin (EBIT margin) 28%* 31%* -3 pp Net profit for the year 4,783 4,706 2% ROIC after tax 17%* 27%* -10 pp Free cash flow -4,731 -6,660 2
Slide 25: Organic growth rates
Organic growth rates 8% 7% 10%* 7% 10% *organic growth for 8 months 26 Bent | user of laryngectomy products
Slide 26: Sales growth per region
Sales growth per region Other developed Emerging markets Europe Markets 9% 5% 14% DKK 6,480m DKK 13,908m DKK 4,112m 27
Slide 27: Operating profit (EBIT)
Operating profit (EBIT) 31 28 6,910 8,845 2021/22 2022/23 Operating profit (EBIT) before special items (DKK million) Operating margin (EBIT, %) before special items 28 Edina | employee
Slide 28: Profit 2022/23
Profit 2022/23 Net profit for the year DKK 4,783m Total assets DKK 48,159m Equity DKK 17,299m Free cash flow for the year DKK -4,731m Dividend DKK 21.00 per DKK 4,657m share Pay-out ratio 97% 29 Jürgen | user of ostomy products
Slide 29: Share price development
Share price development 1.100 1.050 1.000 776 DKK 778 DKK 950 30 September 2022 6 December 2023 900 850 800 750 700 650 600 550 500 10.1.22 11.1.22 12.1.22 1.1.23 2.1.23 3.1.23 4.1.23 5.1.23 6.1.23 7.1.23 8.1.23 9.1.23 10.1.23 11.1.23 12.1.23 Coloplast’s stock price (DKK) 30
Slide 30: Outlook and guidance for 2023/24
Outlook and guidance for 2023/24 Organic growth Reported EBIT Reported growth* margin* ~8% ~12% 27-28% We expect Capex of 1.4bn in DKK. The effective tax rate is expected to be around 22%. *including Kerecis 31
Slide 31: Coloplast Annual General Meeting
Jürgen Coloplast Annual Eva | catheter user Bruger af stomiprodukter General Meeting 2022/23
Slide 32: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 33: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 34: 5. Approval of the remuneration of the Board of Directors
5. Approval of the remuneration of the Board of Directors The Board proposes that the remuneration for the Board for the financial year 2023/24 is: • Ordinary members of the Board are remunerated with a base fee of DKK 450,000. • The Deputy Chairman of the Board is remunerated with a fee of DKK 787,
Slide 35: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 36: 6.1–6.3 Indemnification, Articles of Association, Remuneration Policy
6.1 – 6.3 Indemnification of Board Members, Amendment of Articles of Association, and Update of Remuneration Policy The board proposes that the annual general meeting adopts an updated indemnification scheme for members of the board, as further described in the notice of the annual general meeting.
Slide 37: 6.4. Authorization to acquire treasury shares
6.4. Authorization to the Board of Directors to acquire treasury shares The Board of Directors proposes that the company’s Board of Directors is authorised to allow the company to acquire treasury shares, in one or more stages, for a nominal value of up to DKK 22,820,000 (corresponding to 10% of the
Slide 38: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 39: 7. Election of members to the Board of Directors
7. Election of members to the Board of Directors The Board of Directors proposes re-election of the following members: • Lars Rasmussen • Niels Peter Louis-Hansen • Annette Brüls • Carsten Hellmann • Jette Nygaard-Andersen • Marianne Wiinholt 41
Slide 40: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 41: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 42: Agenda
Agenda 1. Report by the Board of Directors 2. Presentation and approval of the Annual Report 3. Resolution on the distribution of profit 4. Presentation and approval of the Remuneration Report 5. Approval of the remuneration of the Board of Directors 6. Proposals from the Board of Directors 7. Elect
Slide 43: Coloplast
= Coloplast